The Evolving Role of Y90 for Hepatocellular Carcinoma
WebcastOVERVIEW
The Evolving Role of Y90 for Hepatocellular Carcinoma is organized by North American Center for Continuing Medical Education (NACCME) and will be held during Jun 28, 2017 - Jun 28, 2018.
The target audience for this medical event is interventional oncologists, interventional radiologists, medical oncologists, hepatologists, gastroenterologists, surgical oncologists, transplant surgeons, and related healthcare professionals involved in the treatment of hepatocellular carcinoma (HCC). This CME Conference has been approved for a maximum of 1 AMA PRA Category 1 Credit.
Conference Objectives:
After completing this activity, participants should be able to:
• Review recent prospective multicenter trials with focus on hepatocellular carcinoma treatment
• Review current status of intra-arterial therapy for Barcelona Clinic Liver Cancer (BCLC) B Disease
• Identify the current role of intra-arterial therapy in BCLC C Disease
Additional details will be posted as soon as they are available.
The target audience for this medical event is interventional oncologists, interventional radiologists, medical oncologists, hepatologists, gastroenterologists, surgical oncologists, transplant surgeons, and related healthcare professionals involved in the treatment of hepatocellular carcinoma (HCC). This CME Conference has been approved for a maximum of 1 AMA PRA Category 1 Credit.
Conference Objectives:
After completing this activity, participants should be able to:
• Review recent prospective multicenter trials with focus on hepatocellular carcinoma treatment
• Review current status of intra-arterial therapy for Barcelona Clinic Liver Cancer (BCLC) B Disease
• Identify the current role of intra-arterial therapy in BCLC C Disease
Additional details will be posted as soon as they are available.
SPECIALITIES
OncologyHepatologyInterventional Radiology
Quick Links